Table 1.

Demographic and clinical characteristics of patients included in the study cohort

	No NAC (n = 117)						NAC (n = 49)
	High Risk		Low Risk		Total	P value	High Risk		Low Risk		Total	P value
	n	%	n	%	n	n	%	n	%	n
Sex
Female	14	(82.4%)	3	(17.6%)	17	0.03	6	(100%)	0	(0%)	6	0.25
Male	54	(54%)	46	(46%)	100		35	(81.4%)	8	(18.6%)	43
Ethnicity
White	61	(59.2%)	42	(40.8%)	103	0.82	38	(82.6%)	8	(17.4%)	46	0.73
Black	2	(50%)	2	(50%)	4		1	(100%)	0	(0%)	1
Hispanic	3	(42.9%)	4	(57.1%)	7		2	(100%)	0	(0%)	2
Not reported	2	(66.7%)	1	(33.3%)	3		0	(0%)	0	(0%)	0
Hydronephrosis
No	35	(41.7%)	49	(58.3%)	84	< 0.001	24	(75%)	8	(25%)	32	0.02
Yes	33	(100%)	0	(0%)	33		17	(100%)	0	(0%)	17
Lymphovascular invasion
No	46	(48.4%)	49	(51.6%)	95	< 0.001	26	(76.5%)	8	(23.5%)	34	0.04
Yes	22	(100%)	0	(0%)	22		15	(100%)	0	(0%)	15
Aberrant histology
No	62	(55.9%)	49	(44.1%)	111	0.03	27	(77.1%)	8	(22.9%)	35	0.05
Yes	6	(100%)	0	(0%)	6		14	(100%)	0	(0%)	14
Clinical stage
cT2	25	(33.8%)	49	(66.2%)	74	< 0.001	15	(65.2%)	8	(34.8%)	23	0.08
cT3	29	(100%)	0	(0%)	29		21	(100%)	0	(0%)	21
cT4	14	(100%)	0	(0%)	14		5	(100%)	0	(0%)	5
≥cT3b-T4a disease
No	23	(31.9%)	49	(68.1%)	72	< 0.001	13	(61.9%)	8	(38.1%)	21	< 0.001
Yes	45	(100%)	0	(0%)	45		28	(100%)	0	(0%)	28
Post-RC risk classification
High	51	(68.9%)	23	(31.1%)	74	0.002	24	(88.9%)	3	(11.1%)	27	0.27
Low	17	(39.5%)	26	(60.5%)	43		17	(77.3%)	5	(22.7%)	22